Physician profile
Robin A Conner
NPI 1598891376
$3,436.05
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,155 · 2022: $848 · 2023: $932 · 2024: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.83 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.35 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $235.69 | 2021-2022 | |
| Lilly USA, LLC | $233.83 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $185.55 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $155.82 | 2021-2023 | Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $127.73 | 2021-2024 | Breztri, Farxiga |
| Exact Sciences Corporation | $116.08 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.87 | 2021-2024 | Relistor |
| Pfizer INC. | $104.07 | 2021-2023 | |
| Glaxosmithkline, LLC. | $96.82 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $88.15 | 2023-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $78.52 | 2023-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $74.25 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $71.64 | 2021-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.